Ongoing clinical trials of immune-checkpoint inhibitors combined with non-cytotoxic agents

Clinical trial IDPhaseSettingRegimenEndpoint
NCT03041311II1st lineCE plus atezolizumab +/− TrilaciclibOSAEs
NCT02922764I2nd line (solid tumors)RGX-104 +/− NivolumabMTDORRPFS
NCT02712905I/II≥ 2nd line (solid tumors)INCB059872 plus Nivolumab (part 3)AEs
NCT03126110I/II≥ 2nd lineINCAGN01876 plus nivolumab/ipilimumab/nivo+ipiAEsORR
NCT03241173I/II≥ 2nd lineINCAGN01949 plus nivolumab/ipilimumab/nivo+ipiAEsORR
NCT03026166I/II≥ 2nd lineRova-T plus Nivolumab +/− ipilimumabDLT
NCT03085849I2nd lineSGI-110 followed by Durvalumab plus TremelimumabMTD
NCT02734004 (MEDIOLA)I/II2nd lineDurvalumab plus olaparibDCRORRAEs
NCT02554812Ib/II≥ 2nd lineAvelumab plus utomilumabDLTOR

PFS Progression Free Survival, ORR Overall Response Rate, RGX-104 LXR inhibitor, MTD Maximum Tolerated Dose, INCB059872 LSD1 inhibitor, AEs Adverse Events, Rova-T Rovalpituzumab Tesirine, DLT Dose limiting toxicities, INCAGN01876 anti-GITR antibody, INCAGN01949 anti-OX40 antibody, SGI-110 DNMT inhibitor, Trilaciclib CDK4/6 inhibitor, Utomilumab anti-CD137 antibody